n.a. (SHP)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)

Latest News

IIROC Trading Halt - SHP

IIROC Trading Halt - SHP

Europe Stocks Slip as Economic Data and Politics Return to the Fore

Europe Stocks Slip as Economic Data and Politics Return to the Fore

The agenda was dominated by eurozone economic data, the anniversary of Britain's vote to leave the EU and a political summit in Brussels on Friday.

Europe Mixed at Close After Day of Pressure

Europe Mixed at Close After Day of Pressure

Commodity markets, economic growth and the potential for a broad tightening of monetary policy in the developed world over the coming quarters recaptured investors' attention Thursday.

Shire Plc: U.S. FDA Approves Mydayis[TM] (Mixed Salts Of A Single-Entity Amphetamine Product) - A New Once-Daily Option For ADHD Symptom Control In Patients 13 Years And Older

Mydayis demonstrated improvements lasting up to 16 hours post-dose, beginning at 2 or 4 hours post-administration, compared to placebo, in total score on a skill-adjusted math test that measures attention in ADHD

London Stocks Lead Europe Lower Ahead of Election

London Stocks Lead Europe Lower Ahead of Election

European stocks were mixed at the close of Wednesday's session ahead of a key date for both the U.K. and eurozone.

European Stocks Fall as Politics Takes Center Stage

European Stocks Fall as Politics Takes Center Stage

European stocks fell Tuesday as politics returned to forefront of investors' minds, with election talk in Italy and the U.K., and renewed transatlantic sabre rattling, all taking centre stage.

European Stocks Rebound Following Trump Rout

European Stocks Rebound Following Trump Rout

European stocks rebounded Friday as investors shook off the pessimism of recent days, with price action supported by both M&A as well as corporate earnings news.

Shire's Angioedema Success Could Be a Cure for a Bad Record in M&A

Shire's Angioedema Success Could Be a Cure for a Bad Record in M&A

Shire's success in phase 3 trials of Lanadelumab may mean it has also found a cure for a damaged track record in M&A.

Shire Continues 20-Year Commitment To ADHD With New Research At 2017 Annual Meeting Of American Psychiatric Association

Latest Research Supports Greater Understanding of the Evolving Needs of Adults with ADHD

Earnings and Economics Push European Benchmarks Higher

Earnings and Economics Push European Benchmarks Higher

Markets shrugged off weak industrial data from China to focus on economics and earnings news closer to home

Shire Stock Lifted By First-Quarter Earnings Beat

Shire Stock Lifted By First-Quarter Earnings Beat

Shire plc SHP shares shot to the top of the FTSE 100 Tuesday after the drugmaker beat expectations for earnings in the first-quarter and reiterated its full-year guidance.

Shire Granted EU Conditional Marketing Authorisation For Natpar[®¿] (Parathyroid Hormone) For The Treatment Of Patients With Chronic Hypoparathyroidism

Natpar is the first and only licensed recombinant human parathyroid hormone therapy for chronic hypoparathyroidism

Shire Launches #PIPostsThanks Social Campaign To Raise Awareness Of Primary Immunodeficiency (PI)

Shire launches campaign to raise global awareness during World PI Week

PatientsLikeMe And Shire Pharmaceuticals Collaborate To Study Rare Genetic Diseases

PatientsLikeMe and Shire plc (LSE: SHP, NASDAQ: SHPG) have announced a new collaboration that will support the development of a patient-centered, real world health learning system that expands understanding of...

Risky Stocks Rise in Europe but Banks Lag

Risky Stocks Rise in Europe but Banks Lag

Benchmarks were higher on Tuesday following strong gains among commodity, consumer and airline stocks